---
document_datetime: 2025-12-02 05:31:10
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/doptelet.html
document_name: doptelet.html
version: success
processing_time: 0.1075257
conversion_datetime: 2025-12-27 21:50:53.501664
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Doptelet

[RSS](/en/individual-human-medicine.xml/67208)

##### Authorised

This medicine is authorised for use in the European Union

avatrombopag Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Doptelet](#news-on)
- [More information on Doptelet](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Doptelet is a medicine used to prevent excessive bleeding in adults with thrombocytopenia due to long-standing liver disease. Patients with thrombocytopenia have reduced number of platelets (components in the blood that help it to clot), which can cause excessive bleeding.

The medicine is for use in patients having an invasive procedure (a medical procedure that involves cutting into or puncturing the skin or inserting instruments into the body).

Doptelet contains the active substance avatrombopag.

Expand section

Collapse section

## How is Doptelet used?

Doptelet can only be obtained with a prescription. It is available as 20-mg tablets.

Treatment with Doptelet should start at least 10 days before the procedure. The dose is 2 or 3 tablets (depending on the platelet count at the start of treatment), daily for 5 days. A blood test on the day of the procedure is necessary to ensure that the platelet count is adequate and not unexpectedly high.

For more information about using Doptelet, see the package leaflet or contact your doctor or pharmacist.

## How does Doptelet work?

In the body, a hormone called thrombopoietin stimulates the production of platelets by attaching to receptors (targets) in the bone marrow. The active substance in Doptelet, avatrombopag, attaches to the same receptors as thrombopoietin, helping to increase the platelet count.

## What benefits of Doptelet have been shown in studies?

Two main studies in 435 patients with low levels of platelets due to long-standing liver disease found Doptelet effective at increasing platelet levels before an invasive procedure. The main measure of effectiveness was the number of patients who did not require a transfusion of platelets or other treatment ('rescue procedure') to prevent excessive bleeding after starting Doptelet treatment and for up to 7 days after their invasive procedure.

In these studies, 88% of patients who received Doptelet 40 mg daily did not require a transfusion or rescue procedure compared with 36% of patients who were given placebo (a dummy treatment). Among patients with more severe thrombocytopenia, 67% of those given Doptelet 60 mg daily did not require a transfusion or rescue procedure compared with 29% of those who received placebo.

## What are the risks associated with Doptelet?

The most common side effect with Doptelet (which may affect up to 1 in 10 people) is tiredness. For the full list of side effects and restrictions with Doptelet, see the package leaflet.

## Why is Doptelet authorised in the EU?

Studies have found that Doptelet reduced the need for platelet transfusions or other rescue treatments to prevent excessive bleeding before an invasive procedure and for up to 7 days afterward. The platelet count increased in patients treated with Doptelet. Any unwanted effects during treatment with Doptelet were thought to result from patients' medical condition and the nature of the invasive procedure for which it was used.

The European Medicines Agency decided that Doptelet's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Doptelet?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Doptelet have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Doptelet are continuously monitored. Side effects reported with Doptelet are carefully evaluated and any necessary action taken to protect patients.

## Other information about Doptelet

Doptelet received a marketing authorisation valid throughout the EU on 20 June 2019.

Doptelet : EPAR - Medicine overview

Reference Number: EMA/243810/2019

English (EN) (104.1 KB - PDF)

**First published:** 25/06/2019

[View](/en/documents/overview/doptelet-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-524)

български (BG) (169.05 KB - PDF)

**First published:**

25/06/2019

[View](/bg/documents/overview/doptelet-epar-medicine-overview_bg.pdf)

español (ES) (145 KB - PDF)

**First published:**

25/06/2019

[View](/es/documents/overview/doptelet-epar-medicine-overview_es.pdf)

čeština (CS) (167.7 KB - PDF)

**First published:**

25/06/2019

[View](/cs/documents/overview/doptelet-epar-medicine-overview_cs.pdf)

dansk (DA) (142.64 KB - PDF)

**First published:**

25/06/2019

[View](/da/documents/overview/doptelet-epar-medicine-overview_da.pdf)

Deutsch (DE) (146.37 KB - PDF)

**First published:**

25/06/2019

[View](/de/documents/overview/doptelet-epar-medicine-overview_de.pdf)

eesti keel (ET) (132.67 KB - PDF)

**First published:**

25/06/2019

[View](/et/documents/overview/doptelet-epar-medicine-overview_et.pdf)

ελληνικά (EL) (170.53 KB - PDF)

**First published:**

25/06/2019

[View](/el/documents/overview/doptelet-epar-medicine-overview_el.pdf)

français (FR) (146 KB - PDF)

**First published:**

25/06/2019

[View](/fr/documents/overview/doptelet-epar-medicine-overview_fr.pdf)

hrvatski (HR) (166.15 KB - PDF)

**First published:**

25/06/2019

[View](/hr/documents/overview/doptelet-epar-medicine-overview_hr.pdf)

italiano (IT) (142.96 KB - PDF)

**First published:**

25/06/2019

[View](/it/documents/overview/doptelet-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (174.69 KB - PDF)

**First published:**

25/06/2019

[View](/lv/documents/overview/doptelet-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (166.18 KB - PDF)

**First published:**

25/06/2019

[View](/lt/documents/overview/doptelet-epar-medicine-overview_lt.pdf)

magyar (HU) (166.99 KB - PDF)

**First published:**

25/06/2019

[View](/hu/documents/overview/doptelet-epar-medicine-overview_hu.pdf)

Malti (MT) (169.54 KB - PDF)

**First published:**

25/06/2019

[View](/mt/documents/overview/doptelet-epar-medicine-overview_mt.pdf)

Nederlands (NL) (144.45 KB - PDF)

**First published:**

25/06/2019

[View](/nl/documents/overview/doptelet-epar-medicine-overview_nl.pdf)

polski (PL) (171.38 KB - PDF)

**First published:**

25/06/2019

[View](/pl/documents/overview/doptelet-epar-medicine-overview_pl.pdf)

português (PT) (145.48 KB - PDF)

**First published:**

25/06/2019

[View](/pt/documents/overview/doptelet-epar-medicine-overview_pt.pdf)

română (RO) (164.96 KB - PDF)

**First published:**

25/06/2019

[View](/ro/documents/overview/doptelet-epar-medicine-overview_ro.pdf)

slovenčina (SK) (167.13 KB - PDF)

**First published:**

25/06/2019

[View](/sk/documents/overview/doptelet-epar-medicine-overview_sk.pdf)

slovenščina (SL) (163.94 KB - PDF)

**First published:**

25/06/2019

[View](/sl/documents/overview/doptelet-epar-medicine-overview_sl.pdf)

Suomi (FI) (142.78 KB - PDF)

**First published:**

25/06/2019

[View](/fi/documents/overview/doptelet-epar-medicine-overview_fi.pdf)

svenska (SV) (143.17 KB - PDF)

**First published:**

25/06/2019

[View](/sv/documents/overview/doptelet-epar-medicine-overview_sv.pdf)

Doptelet : EPAR - Risk-management-plan summary

English (EN) (293.18 KB - PDF)

**First published:** 25/06/2019

**Last updated:** 28/01/2021

[View](/en/documents/rmp-summary/doptelet-epar-risk-management-plan-summary_en.pdf)

## Product information

Doptelet : EPAR - Product information

English (EN) (322.06 KB - PDF)

**First published:** 25/06/2019

**Last updated:** 18/06/2025

[View](/en/documents/product-information/doptelet-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-469)

български (BG) (459.11 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/bg/documents/product-information/doptelet-epar-product-information_bg.pdf)

español (ES) (321.92 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/es/documents/product-information/doptelet-epar-product-information_es.pdf)

čeština (CS) (407.65 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/cs/documents/product-information/doptelet-epar-product-information_cs.pdf)

dansk (DA) (304.43 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/da/documents/product-information/doptelet-epar-product-information_da.pdf)

Deutsch (DE) (330.38 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/de/documents/product-information/doptelet-epar-product-information_de.pdf)

eesti keel (ET) (308.38 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/et/documents/product-information/doptelet-epar-product-information_et.pdf)

ελληνικά (EL) (545.72 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/el/documents/product-information/doptelet-epar-product-information_el.pdf)

français (FR) (320.22 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/fr/documents/product-information/doptelet-epar-product-information_fr.pdf)

hrvatski (HR) (392.07 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/hr/documents/product-information/doptelet-epar-product-information_hr.pdf)

íslenska (IS) (304.54 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/is/documents/product-information/doptelet-epar-product-information_is.pdf)

italiano (IT) (317.62 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/it/documents/product-information/doptelet-epar-product-information_it.pdf)

latviešu valoda (LV) (410.63 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/lv/documents/product-information/doptelet-epar-product-information_lv.pdf)

lietuvių kalba (LT) (425.35 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/lt/documents/product-information/doptelet-epar-product-information_lt.pdf)

magyar (HU) (413.19 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/hu/documents/product-information/doptelet-epar-product-information_hu.pdf)

Malti (MT) (498.55 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/mt/documents/product-information/doptelet-epar-product-information_mt.pdf)

Nederlands (NL) (314 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/nl/documents/product-information/doptelet-epar-product-information_nl.pdf)

norsk (NO) (328.96 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/no/documents/product-information/doptelet-epar-product-information_no.pdf)

polski (PL) (421.85 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/pl/documents/product-information/doptelet-epar-product-information_pl.pdf)

português (PT) (347.52 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/pt/documents/product-information/doptelet-epar-product-information_pt.pdf)

română (RO) (420.91 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/ro/documents/product-information/doptelet-epar-product-information_ro.pdf)

slovenčina (SK) (426.22 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/sk/documents/product-information/doptelet-epar-product-information_sk.pdf)

slovenščina (SL) (389.44 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/sl/documents/product-information/doptelet-epar-product-information_sl.pdf)

Suomi (FI) (306 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/fi/documents/product-information/doptelet-epar-product-information_fi.pdf)

svenska (SV) (327.44 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

18/06/2025

[View](/sv/documents/product-information/doptelet-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000255149 22/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Doptelet : EPAR - All authorised presentations

English (EN) (17.2 KB - PDF)

**First published:** 25/06/2019

**Last updated:** 28/01/2021

[View](/en/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-223)

български (BG) (40.22 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/bg/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_bg.pdf)

español (ES) (17.33 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/es/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_es.pdf)

čeština (CS) (41.16 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/cs/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (22.04 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/da/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (17.07 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/de/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (17.15 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/et/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (40.1 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/el/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_el.pdf)

français (FR) (17.12 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/fr/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (26.21 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/hr/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (16.95 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/is/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_is.pdf)

italiano (IT) (17.21 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/it/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (39.09 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/lv/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (39.28 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/lt/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (25.48 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/hu/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (35.47 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/mt/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (17.1 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/nl/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (17.17 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/no/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_no.pdf)

polski (PL) (28.14 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/pl/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_pl.pdf)

português (PT) (17.17 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/pt/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_pt.pdf)

română (RO) (37.28 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/ro/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (27.04 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/sk/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (25.6 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/sl/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.13 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/fi/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (17.01 KB - PDF)

**First published:**

25/06/2019

**Last updated:**

28/01/2021

[View](/sv/documents/all-authorised-presentations/doptelet-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Doptelet Active substance avatrombopag maleate International non-proprietary name (INN) or common name avatrombopag Therapeutic area (MeSH) Thrombocytopenia Anatomical therapeutic chemical (ATC) code B02BX

### Pharmacotherapeutic group

Antihemorrhagics

### Therapeutic indication

Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.

Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

## Authorisation details

EMA product number EMEA/H/C/004722 Marketing authorisation holder

Swedish Orphan Biovitrum AB (publ)

SE-112 76 Stockholm

Opinion adopted 26/04/2019 Marketing authorisation issued 20/06/2019 Revision 10

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Doptelet : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (167.99 KB - PDF)

**First published:** 18/06/2025

[View](/en/documents/procedural-steps-after/doptelet-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Doptelet : EPAR - Procedural steps taken and scientific information after the authorisation (archive)

English (EN) (126.55 KB - PDF)

**First published:** 27/01/2020

**Last updated:** 18/06/2025

[View](/en/documents/procedural-steps-after/doptelet-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Doptelet-H-C-004722-P46-007 : EPAR - Assessment report - Variation

Reference Number: EMA/369609/2024

English (EN) (1.25 MB - PDF)

**First published:** 13/08/2024

[View](/en/documents/variation-report/doptelet-h-c-004722-p46-007-epar-assessment-report-variation_en.pdf)

Doptelet-H-C-PSUSA-00010779-202005 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/197652/2021

English (EN) (126.76 KB - PDF)

**First published:** 07/04/2021

[View](/en/documents/scientific-conclusion/doptelet-h-c-psusa-00010779-202005-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Doptelet-H-C-004722-II-0004-G : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/7081/2021

English (EN) (11.37 MB - PDF)

**First published:** 28/01/2021

[View](/en/documents/variation-report/doptelet-h-c-004722-ii-0004-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Doptelet (II-04-G)

Adopted

Reference Number: EMA/CHMP/659983/2020

English (EN) (100.12 KB - PDF)

**First published:** 11/12/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-doptelet-ii-04-g_en.pdf)

## Initial marketing authorisation documents

Doptelet : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/322871/2019

English (EN) (5.43 MB - PDF)

**First published:** 25/06/2019

[View](/en/documents/assessment-report/doptelet-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Doptelet

Adopted

Reference Number: EMA/CHMP/208938/2019

English (EN) (113.92 KB - PDF)

**First published:** 26/04/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-doptelet_en.pdf)

#### News on Doptelet

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020) 11/12/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019) 26/04/2019

#### More information on Doptelet

- [EMEA-001136-PIP01-11-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001136-pip01-11-m03)
- [EMEA-001136-PIP02-19-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001136-pip02-19-m01)
- [Postauthorisation Safety Study (PASS) of Avatrombopag in Patients With Severe Chronic Liver Disease (CLD) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000310)
- [Postauthorisation Safety Study (PASS) of Avatrombopag and Haematological Malignancies in Patients With Primary Immune Thrombocytopaenia - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000315)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 18/06/2025

## Share this page

[Back to top](#main-content)